Finally, as the pharmacodynamic mechanism of GR antagonism does not allow to rely on biochemical markers of CS due to the compensatory rise in circulating cortisol levels, clinicians should evaluate treatment efficacy by monitoring hypercortisolism-related clinical syndrome and comorbidities, an approach uneasy to perform in clinical practice (4). Here, NR3C1 is linked to Cowden syndrome 1.